Howe & Rusling’s DexCom DXCM Stock Holding History

Howe & Rusling’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-56	Closed	-$5K	–	968
2021 Q1	$5K	Sell	56 -392	-88%	-$36.8K	﹤0.01%	611
2020 Q4	$41K	Buy	+448	New	+$40K	0.01%	299

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Howe & Rusling's DXCM Position: Q2 2021 in Review

Howe & Rusling sold out of DexCom (DXCM) in Q2 2021, closing a stake of 56 shares — an estimated $5K sold.

Howe & Rusling first reported a position in DXCM in Q4 2020 and held it in 2 quarters. The position peaked at $41K in Q4 2020. 726 funds tracked by Wall St. Rank hold DXCM as of Q2 2021.

Howe & Rusling reported no remaining DexCom position as of Q2 2021 after selling out during the quarter.
Howe & Rusling sold 56 DexCom shares in Q2 2021, an estimated $5K.
Howe & Rusling first reported a position in DexCom in Q4 2020 and held it in 2 quarters.
Howe & Rusling's DexCom position peaked at $41K in Q4 2020.
726 funds tracked by Wall St. Rank held DexCom as of Q2 2021.

Based on Howe & Rusling's 13F filing for Q2 2021, filed 13 Aug 2021.